Close Menu

phase I clinical study

The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.

The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.

The Phase I/II trial will assess the safety and efficacy of the CAR T cell therapy MB-102 for patients with three types of hematologic malignancies.

The Phase I trial evaluated the safety and maximum tolerated dose of BAY-1895344 along with objective response rate among patients with DDR deficiencies.

The Swiss company will assess the agent both alone and combined with Tecentriq as a treatment for FGFR-positive gastric cancer.

The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.

The trial, which received positive feedback from the FDA, will enroll patients who have a biomarker that may increase their chances of responding to the drug.

The company is developing T-cell receptor therapies, several of which have entered early-phase trials, that target unique peptides identified through mass spectrometry.

The trial will assess the safety and tolerability of Zion's ZN-A-1041 in patients with HER2-positive tumors, including those with brain metastases.